Literature DB >> 20526382

Effect of Peptide-Chelate Architecture on Metabolic Stability of Peptide-based MRI Contrast Agents.

Zhaoda Zhang1, Andrew F Kolodziej, Jianfeng Qi, Shrikumar A Nair, Xifang Wang, April W Case, Matthew T Greenfield, Philip B Graham, Thomas J McMurry, Peter Caravan.   

Abstract

A strategy for preparing high relaxivity, metabolically stable peptide-based MR contrast agents is described.

Entities:  

Year:  2010        PMID： 20526382      PMCID： PMC2880861          DOI： 10.1039/b9nj00787c

Source DB:  PubMed          Journal:  New J Chem        ISSN： 1144-0546            Impact factor:   3.591


  18 in total

Review 1.  The role of coordination chemistry in the development of target-specific radiopharmaceuticals.

Authors:  Shuang Liu
Journal:  Chem Soc Rev       Date:  2004-08-16       Impact factor: 54.564

2.  Micelles derivatized with octreotide as potential target-selective contrast agents in MRI.

Authors:  Anna Morisco; Antonella Accardo; Eliana Gianolio; Diego Tesauro; Ettore Benedetti; Giancarlo Morelli
Journal:  J Pept Sci       Date:  2009-03       Impact factor: 1.905

3.  Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.

Authors:  Peter Caravan
Journal:  Acc Chem Res       Date:  2009-07-21       Impact factor: 22.384

4.  The (DD)E complex is maintained by a composite fibrin polymerization site.

Authors:  K A Moskowitz; A Z Budzynski
Journal:  Biochemistry       Date:  1994-11-08       Impact factor: 3.162

5.  Specific interactions outside the proline-rich core of two classes of Src homology 3 ligands.

Authors:  S Feng; C Kasahara; R J Rickles; S L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

6.  Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes.

Authors:  Young-Seung Kim; Zhengjie He; Wen-Yuan Hsieh; Shuang Liu
Journal:  Bioconjug Chem       Date:  2007-03-13       Impact factor: 4.774

7.  MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients.

Authors:  Elmar Spuentrup; Rene M Botnar; Andrea J Wiethoff; Tareq Ibrahim; Sebastian Kelle; Marcus Katoh; Murat Ozgun; Eike Nagel; Josef Vymazal; Phil B Graham; Rolf W Günther; David Maintz
Journal:  Eur Radiol       Date:  2008-04-19       Impact factor: 5.315

8.  Atherosclerosis and matrix metalloproteinases: experimental molecular MR imaging in vivo.

Authors:  Vardan Amirbekian; Juan Gilberto S Aguinaldo; Smbat Amirbekian; Fabien Hyafil; Esad Vucic; Marc Sirol; David B Weinreb; Soizic Le Greneur; Eric Lancelot; Claire Corot; Edward A Fisher; Zorina S Galis; Zahi A Fayad
Journal:  Radiology       Date:  2009-05       Impact factor: 11.105

9.  EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

Authors:  Kirsten Overoye-Chan; Steffi Koerner; Richard J Looby; Andrew F Kolodziej; Stephan G Zech; Qing Deng; Jaclyn M Chasse; Thomas J McMurry; Peter Caravan
Journal:  J Am Chem Soc       Date:  2008-04-08       Impact factor: 15.419

10.  A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.

Authors:  Furong Ye; Xueming Wu; Eun-Kee Jeong; Zhanjun Jia; Tianxin Yang; Denis Parker; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774
View more
  13 in total

1.  Fibrin specific peptides derived by phage display: characterization of peptides and conjugates for imaging.

Authors:  Andrew F Kolodziej; Shrikumar A Nair; Philip Graham; Thomas J McMurry; Robert C Ladner; Charles Wescott; Daniel J Sexton; Peter Caravan
Journal:  Bioconjug Chem       Date:  2012-02-09       Impact factor: 4.774

2.  Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis.

Authors:  Pauline Désogère; Luis F Tapias; Tyson A Rietz; Nicholas Rotile; Francesco Blasi; Helen Day; Justin Elliott; Bryan C Fuchs; Michael Lanuti; Peter Caravan
Journal:  J Nucl Med       Date:  2017-06-13       Impact factor: 10.057

3.  A modular system for the synthesis of multiplexed magnetic resonance probes.

Authors:  Daniel J Mastarone; Victoria S R Harrison; Amanda L Eckermann; Giacomo Parigi; Claudio Luchinat; Thomas J Meade
Journal:  J Am Chem Soc       Date:  2011-03-17       Impact factor: 15.419

4.  Structure - relaxivity relationships among targeted MR contrast agents.

Authors:  Peter Caravan; Zhaoda Zhang
Journal:  Eur J Inorg Chem       Date:  2012-04       Impact factor: 2.524

5.  Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity.

Authors:  Zhaoda Zhang; Andrew F Kolodziej; Matthew T Greenfield; Peter Caravan
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-08       Impact factor: 15.336

Review 6.  MR imaging probes: design and applications.

Authors:  Eszter Boros; Eric M Gale; Peter Caravan
Journal:  Dalton Trans       Date:  2015-03-21       Impact factor: 4.390

7.  Fibrin-targeted PET probes for the detection of thrombi.

Authors:  Katie L Ciesienski; Yan Yang; Ilknur Ay; Daniel B Chonde; Galen S Loving; Tyson A Rietz; Ciprian Catana; Peter Caravan
Journal:  Mol Pharm       Date:  2013-01-30       Impact factor: 4.939

Review 8.  Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers.

Authors:  Jessica Wahsner; Eric M Gale; Aurora Rodríguez-Rodríguez; Peter Caravan
Journal:  Chem Rev       Date:  2018-10-16       Impact factor: 60.622

9.  Molecular imaging of fibrin in a breast cancer xenograft mouse model.

Authors:  Ritika Uppal; Zdravka Medarova; Christian T Farrar; Guangping Dai; Anna Moore; Peter Caravan
Journal:  Invest Radiol       Date:  2012-10       Impact factor: 6.016

10.  A new ditopic Gd(III) complex functionalized with an adamantyl moiety as a versatile building block for the preparation of supramolecular assemblies.

Authors:  Giuseppe Gambino; Sara De Pinto; Lorenzo Tei; Claudio Cassino; Francesca Arena; Eliana Gianolio; Mauro Botta
Journal:  J Biol Inorg Chem       Date:  2013-10-08       Impact factor: 3.358
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.